A detailed history of Tybourne Capital Management (Hk) LTD transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Tybourne Capital Management (Hk) LTD holds 1,509,713 shares of BCYC stock, worth $35 Million. This represents 7.67% of its overall portfolio holdings.

Number of Shares
1,509,713
Previous 1,545,026 2.29%
Holding current value
$35 Million
Previous $38.5 Million 20.57%
% of portfolio
7.67%
Previous 8.61%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$20.02 - $24.69 $706,966 - $871,877
-35,313 Reduced 2.29%
1,509,713 $30.6 Million
Q1 2024

May 15, 2024

SELL
$16.75 - $26.1 $1.76 Million - $2.75 Million
-105,294 Reduced 6.38%
1,545,026 $38.5 Million
Q4 2023

Feb 14, 2024

BUY
$13.29 - $22.2 $4.9 Million - $8.18 Million
368,500 Added 28.75%
1,650,320 $29.8 Million
Q2 2023

Aug 14, 2023

SELL
$18.95 - $28.67 $2.41 Million - $3.64 Million
-127,011 Reduced 9.02%
1,281,820 $32.7 Million
Q1 2023

May 15, 2023

BUY
$20.02 - $31.37 $10.1 Million - $15.8 Million
503,109 Added 55.55%
1,408,831 $30 Million
Q4 2022

Feb 14, 2023

SELL
$20.37 - $32.9 $2.76 Million - $4.46 Million
-135,609 Reduced 13.02%
905,722 $26.8 Million
Q3 2022

Nov 14, 2022

SELL
$17.49 - $28.44 $1.97 Million - $3.21 Million
-112,795 Reduced 9.77%
1,041,331 $24.2 Million
Q1 2022

May 04, 2022

SELL
$40.12 - $59.5 $36.1 Million - $53.5 Million
-899,678 Reduced 43.81%
1,154,126 $50.6 Million
Q4 2021

Jan 26, 2022

BUY
$41.7 - $61.14 $4 Million - $5.86 Million
95,843 Added 4.9%
2,053,804 $125 Million
Q2 2019

Aug 14, 2019

BUY
$10.06 - $14.63 $19.7 Million - $28.6 Million
1,957,961 New
1,957,961 $19.7 Million

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $689M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Tybourne Capital Management (Hk) LTD Portfolio

Follow Tybourne Capital Management (Hk) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tybourne Capital Management (Hk) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Tybourne Capital Management (Hk) LTD with notifications on news.